High-yield T lymphocyte cloning technology for finding tumor specific antigen and tumor specific antigen determinant
A tumor-specific, lymphocyte-based technology, applied in the field of high-yield T-lymphocyte cloning technology, can solve problems such as T-lymphocyte death
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Publication Date
- 2005-04-27
- Estimated Expiration
- Not applicable · inactive patent
Smart Images
Figure 1
Abstract
Description
technical field
[0001] The invention relates to the field of tumor immunology, and further, the invention relates to a high-yield T lymphocyte cloning technique for discovering tumor-specific antigens and tumor-specific antigenic determinants. Background technique
[0002] Many studies have shown that the control and treatment of cancer can be achieved by manipulating the human immune system. For example, using the body's mucus immune response, monoclonal antibodies can be developed against various growth factor receptors and cell surface marker molecules to achieve the goal of treating cancer. effect; on the other hand, the use of cellular immune response to activate the human immune system to specifically kill tumor cells to achieve the treatment of cancer has been paid more and more attention.
[0003] The cellular immune response of the human immune system is mainly realized through T lymphocytes (Tlymphocytes). T lymphocytes can be divided into CD8-positive killer T ly...
Examples
Embodiment 1
[0043] As shown in Figure 1, a typical example of HITC technology can be described as follows:
[0044] 1. Identify and expand tumor-reactive T lymphocytes
[0045] 1. Excision of tumor samples: Tumor samples are obtained from patients.
[0046] 2. Single-cell suspension: A part of the tumor sample is treated with various enzymes or processed by automatic mechanical force to make it into a single-cell suspension.
[0047] 3. Cell separation: use antibody-coated magnetic beads to separate CD4-positive and CD8-positive cells, while the remaining cells (mainly tumor cells) are cultured as attached cells.
[0048] 4. Limiting dilution with STIMULEUKIN (new auxin mixture): Based on the need for T lymphocyte cloning, the isolated CD4-positive and CD8-positive T lymphocytes are diluted, and then point to cultures that have been killed by irradiation. Cell-covered 96-well plates, with a maximum of one cell per well, are injected with STIMULEUKIN to expand these single-cell clones. ...